Empagliflozin & LinagliptinSGLT2 Inhibitor & DPP-4 Inhibitor Combination (Antidiabetic Preparations) Indication: GlympaTM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. Dosage & Administration: […]